Translational Research &Pharmacology Core Program Director/Principal Investigator: Gerson, Stanton L. PROJECT SUMMARY (See instructions): The primary role of the Translation Research &Pharmacology Core is to facilitate the implementation of scientifically rigorous correlative study components for Case CCC clinical trials. The Core has four components - a central office and cellular and molecular biology lab;a clinical processing lab;a clinical pharmacology lab;and a cancer pharmacology (mass spectrometry) lab. Core staff is composed of an experienced team dedicated to facilitating all aspects of the correlative study components of Case CCC clinical trials, guaranteeing consistent quality control. The TRC also includes an effort initially supported with UOl funds to perform in vitro testing of new drugs and combination therapies. The central, clinical processing and pharmacology labs are administered by the Case CCC, while the clinical pharmacology lab is managed through Cleveland Clinic, but is part of this Core operation. The service is to support correlative studies within Case CCC clinical trials. Support from the CCSG stabilizes the Core financially and provides clinical investigators formal ability to obtain clinical correlates. Formal access to Core services is extended to Case CCC members across the consortium sites. Services provided by the Core include: 1) consultation or full service writing of methods sections and budgets for CTEP letters of intent, protocols, and grants;2) sample informatics and correlate data;3) data analysis;4) sample handling (receiving, storage, distribution);5) sample processing (dispensing whole blood aliquots, routine blood processing, DNA, RNA and protein extraction, flow or laser scanning cytometry staining);6) lab analysis (western blots, ELISAs, MSD multiplex analysis, PARP activity and Poly(ADP)-ribose assay, comet assays);7) single or multiple agent cytotoxicity multiple agent analysis), 8) pharmacokinetic assay development, and 9) pharmacokinetic assay performance. The Core handles specimens from ~100 trials per year, members from all of the Case CCC Scientific Research Programs utilize the Core, and the user base is >95% Case CCC membership. The Core played a key role in numerous projects including: the first-in-human trial of the base excision inhibitor methoxyamine used in combination with temozolomide (Cancer Pharmacology Lab) and the design and operation ofthe Gl SPORE Biospecimen Core.

Public Health Relevance

The Case Comprehensive Cancer Center is Northeast Ohio's only NCI designated comprehensive cancer center providing bench-to-bedside medical research involving partnerships between basic, clinical and population scientists to speed translation of laboratory discoveries into new prevention/intervention and cancer treatments.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA043703-24
Application #
8765400
Study Section
Subcommittee B - Comprehensiveness (NCI)
Project Start
Project End
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
24
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Case Western Reserve University
Department
Type
DUNS #
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Cummings III, Kenneth C; Zimmerman, Nicole M; Maheshwari, Kamal et al. (2018) Epidural compared with non-epidural analgesia and cardiopulmonary complications after colectomy: A retrospective cohort study of 20,880 patients using a national quality database. J Clin Anesth 47:12-18
Thiagarajan, Praveena S; Sinyuk, Maksim; Turaga, Soumya M et al. (2018) Cx26 drives self-renewal in triple-negative breast cancer via interaction with NANOG and focal adhesion kinase. Nat Commun 9:578
Qiu, Zhaojun; Oleinick, Nancy L; Zhang, Junran (2018) ATR/CHK1 inhibitors and cancer therapy. Radiother Oncol 126:450-464
Elitt, Matthew S; Shick, H Elizabeth; Madhavan, Mayur et al. (2018) Chemical Screening Identifies Enhancers of Mutant Oligodendrocyte Survival and Unmasks a Distinct Pathological Phase in Pelizaeus-Merzbacher Disease. Stem Cell Reports 11:711-726
He, Tian; McColl, Karen; Sakre, Nneha et al. (2018) Post-transcriptional regulation of PIAS3 expression by miR-18a in malignant mesothelioma. Mol Oncol 12:2124-2135
Roche, Kathryn L; Nukui, Masatoshi; Krishna, Benjamin A et al. (2018) Selective 4-Thiouracil Labeling of RNA Transcripts within Latently Infected Cells after Infection with Human Cytomegalovirus Expressing Functional Uracil Phosphoribosyltransferase. J Virol 92:
Bedell, Hillary W; Hermann, John K; Ravikumar, Madhumitha et al. (2018) Targeting CD14 on blood derived cells improves intracortical microelectrode performance. Biomaterials 163:163-173
Nagaraj, A B; Wang, Q Q; Joseph, P et al. (2018) Using a novel computational drug-repositioning approach (DrugPredict) to rapidly identify potent drug candidates for cancer treatment. Oncogene 37:403-414
Somasegar, Sahana; Li, Li; Thompson, Cheryl L (2018) No association of reproductive risk factors with breast cancer tumor grade. Eur J Cancer Prev 27:140-143
Gu, Xiaorong; Ebrahem, Quteba; Mahfouz, Reda Z et al. (2018) Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates. J Clin Invest 128:4260-4279

Showing the most recent 10 out of 1227 publications